Investigational drug · Phase 3
ACC017
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Infection, Human Immunodeficiency Virus.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "ACC017"
First trial start
2024
Aug 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACC017", any sponsor or status.
Conditions studied
As listed on its trial records.
- Infection, Human Immunodeficiency Virus
Approved drugs for the same conditions: Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ACC017" as an intervention, largest first.
- Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)Pivotal-lookingActive, not recruiting
Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
NCT07711223 · 660 participants (planned) · Start Nov 7, 2025 · Primary completion Aug 31, 2028
Drug: ACC017+FTC/TAF; DTG+FTC/TAF · For: Infection, Human Immunodeficiency Virus
Sites: Beijing, China
- Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting ConditionsCompleted
Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
NCT07753902 · 48 participants · Start Apr 10, 2026 · Primary completion May 18, 2026
Drug: ACC118-Test; Reference · For: Human Immunodeficiency Virus (HIV) Infection
Sites: Chizhou, China
Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
NCT06278389 · 48 participants · Start Jan 24, 2024 · Primary completion May 20, 2024
Drug: ACC017 tablets; Emtricitabine and Tenofovir Alafenamide Fumarate Tablets · For: Healthy Adult Participants
Sites: Beijing, China
Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
NCT06719310 · 36 participants · Start Aug 28, 2024 · Primary completion Apr 28, 2025
Drug: ACC017+FTC/TAF; Placebo · For: Infection, Human Immunodeficiency Virus
Sites: Beijing, China
- Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance MutationsActive, not recruiting
Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
NCT07711210 · 12 participants · Start Mar 21, 2025 · Primary completion Jun 30, 2027
Drug: ACC017; Placebo · For: Infection, Human Immunodeficiency Virus
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Anti-HIV-1 Activity of the Integrase Strand Transfer Inhibitor ACC017.
Ma MD, Luo RH, Li CY, et al. · Viruses 2025
Also in development for Infection, Human Immunodeficiency Virus
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
- FTCPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.